What we're reading, March 2, 2016: FDA commissioner pledges stronger efforts to develop harder-to-abuse painkillers; Olympus Corp. agrees to largest settlement for violating anti-kickback laws; and the Supreme Court hears Texas abortion case with just 8 members on the bench.
When the new FDA commissioner, Robert Califf, MD, was confirmed last week, it was over concerns from some senators that his agency had not done enough to combat the rising painkiller abuse epidemic. Now, Dr Califf is pledging to back efforts to develop painkillers that are harder to abuse, reported the AP. Since 2010, the FDA has approved 5 abuse-deterrent drugs and there are at least 30 similar drugs currently in development.
Olympus Corp. will pay $646 million to resolve probes into illegal kickbacks and bribes to doctors and hospitals. According to Kaiser Health News, the company, which is already under investigation for its role in superbug outbreaks, has used research grants, consulting deals, luxury trips and more to influence doctors to order more Olympus devices at hospitals. The company’s settlement is the largest ever for a kickback violation.
On Wednesday a closely watched abortion case went before the US Supreme Court. With only 8 justices on the bench, the court no longer has 5 conservatives who might support more restrictive abortion regulations nationwide, reported Reuters. The case focuses on whether a Texas law imposing strict regulations interferes with a woman’s constitutional right to end her pregnancy. If the court splits 4-4, the lower court’s ruling would stand, which would affirm the Texas law. The last time the Supreme Court ruled on an abortion case was 2007.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More